Hoth Therapeutics Files Q3 2024 10-Q Report

Ticker: HOTH · Form: 10-Q · Filed: 2024-11-12T00:00:00.000Z

Sentiment: neutral

Topics: 10-Q, quarterly-report, pharmaceuticals

TL;DR

HOTH filed its 10-Q for Q3 2024. Check financials.

AI Summary

Hoth Therapeutics, Inc. filed its quarterly report on Form 10-Q for the period ending September 30, 2024. The company, incorporated in Nevada, is involved in the pharmaceutical preparations industry. Its principal executive offices are located at 590 Madison Avenue, New York, NY.

Why It Matters

This filing provides investors with an update on Hoth Therapeutics' financial performance and operational status for the third quarter of 2024.

Risk Assessment

Risk Level: low — This is a routine quarterly filing providing standard financial and operational information.

Key Numbers

Key Players & Entities

FAQ

What is the primary business of Hoth Therapeutics, Inc.?

Hoth Therapeutics, Inc. is primarily involved in Pharmaceutical Preparations, as indicated by its SIC code [2834].

For which fiscal period is this 10-Q report filed?

This 10-Q report is filed for the quarterly period ended September 30, 2024.

Where are Hoth Therapeutics, Inc.'s principal executive offices located?

The principal executive offices of Hoth Therapeutics, Inc. are located at 590 Madison Avenue, 21st Floor, New York, NY 10022.

What is the Commission File Number for Hoth Therapeutics, Inc.?

The Commission File Number for Hoth Therapeutics, Inc. is 001-38803.

In which state was Hoth Therapeutics, Inc. incorporated?

Hoth Therapeutics, Inc. was incorporated in Nevada.

From the Filing

0001213900-24-096778.txt : 20241112 0001213900-24-096778.hdr.sgml : 20241112 20241112160531 ACCESSION NUMBER: 0001213900-24-096778 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 62 CONFORMED PERIOD OF REPORT: 20240930 FILED AS OF DATE: 20241112 DATE AS OF CHANGE: 20241112 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Hoth Therapeutics, Inc. CENTRAL INDEX KEY: 0001711786 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 821553794 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-38803 FILM NUMBER: 241447967 BUSINESS ADDRESS: STREET 1: 590 MADISON AVENUE STREET 2: 21ST FLOOR CITY: NEW YORK STATE: NY ZIP: 10022 BUSINESS PHONE: (646)756-2997 MAIL ADDRESS: STREET 1: 590 MADISON AVENUE STREET 2: 21ST FLOOR CITY: NEW YORK STATE: NY ZIP: 10022 10-Q 1 ea0219583-10q_hoththera.htm QUARTERLY REPORT     UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549   FORM  10-Q   (Mark One) ☒   QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934   For the Quarterly Period Ended: September 30, 2024   ☐   TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934   For the transition period from:   Commission File Number: 001-38803   Hoth Therapeutics, Inc. (Exact name of registrant as specified in its charter)   Nevada   82-1553794 (State or other jurisdiction of   (I.R.S. Employer incorporation or organization)   Identification No.)   590 Madison Ave ., 21 st Floor New York , NY   10022 (Address of principal executive offices)   (Zip Code)   (646) 756-2997 (Registrant’s telephone number, including area code)   Not applicable (Former name, former address and former fiscal year, if changed since last report)   Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading symbol(s)   Name of each exchange on which registered Common Stock, $0.0001 par value   HOTH   The Nasdaq Stock Market LLC   Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐   Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐   Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.   Large accelerated filer ☐ Accelerated filer ☐ Non-accelerated filer ☒ Smaller reporting company ☒     Emerging growth company ☒   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐   Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒   The number of shares of the issuer’s common stock,

View on Read The Filing